Redeye resumes coverage and updates its view on Nanologica following the equity issues, the Syntagon acquisition, and the Q1 2026 report. Post the acquisition the group now sports a run rate of ~SEK100m with the chromatography business adding sales acceleration optionality on top. The valuation stands at ~1.6x EV/S for FY 2026e.
LÄS MER
